Issue 4, 2014

Emerging classes of armed antibody therapeutics against cancer

Abstract

Monoclonal antibodies represent the largest and fastest growing type of biopharmaceuticals. Their commercial and clinical success has fueled research activities aiming to improve safety and efficacy. In oncology, there is a trend towards the development of ‘armed’ antibody products, in which the immunoglobulin moiety serves for the selective in vivo pharmacodelivery of bioactive payloads such as cytotoxic drugs, bispecific antibodies, radionuclides or cytokines to sites of disease, thereby sparing healthy tissues. In this article, we review some of the most advanced preclinical and clinical activities in the field of armed antibodies and present a personal perspective on the opportunities and challenges associated with the use of this type of anti-cancer therapeutics.

Graphical abstract: Emerging classes of armed antibody therapeutics against cancer

Article information

Article type
Review Article
Submitted
27 Nov 2013
Accepted
18 Dec 2013
First published
07 Jan 2014

Med. Chem. Commun., 2014,5, 408-431

Emerging classes of armed antibody therapeutics against cancer

C. Hess, D. Venetz and D. Neri, Med. Chem. Commun., 2014, 5, 408 DOI: 10.1039/C3MD00360D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements